Business
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. DUBLIN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (“Avadel” or the “Company”) announces today that, in relation to the previously announced offer for the Company by Alkermes plc, a public limited company incorporate
About this update from Alkermes Plc
[{"type":"image","alt":"Avadel Pharmaceuticals plc","displaySize":"","headline":null,"caption":"Avadel Pharmaceuticals plc","className":"","disableSlideshowImg":false,"size":{"original":{"width":174,"height":44,"url":"https://media.zenfs.com/en/globenewswire.com/824110bbcc617e195eecffbaba7ce541"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xA8MjS17.F7U66LIX3QbTw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/824110bbcc617e195eecffbaba7ce541","width":174,"height":44}},"lazy":false},{"type":"text","content":"NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.","length":200,"tagName":"p"},{"type":"text","content":"DUBLIN, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a public limited company incorporated in Ireland (“Avadel” or the “Company”) announces today that, in relation to the previously announced offer for the Company by Alkermes plc, a public limited company incorporated in Ireland (“Alkermes”), pursuant to which Alkermes will acquire the entire issued and to be issued ordinary share capital of the Company (the “Proposed Transaction”), the resolutions required to approve the scheme of arrangement under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the “Scheme”) were passed by the requisite majorities at the scheme meeting of shareholders (the “Scheme Meeting”) and the related extraordinary general meeting of shareholders (“EGM”) held earlier today.","length":794,"tagName":"p"},{"type":"text","content":"Full details of the resolutions passed are set out in the notices of the Scheme Meeting and EGM contained in the definitive proxy statement filed by Avadel with the U.S. Securities and Exchange Commission (“SEC”) on December 3, 2025 (the “Definitive Proxy Statement”). A quorum was present at each of the Scheme Meeting and the EGM, being five or more registered holders of Avadel shares holding a majority of the voting power of Avadel shares as of 5.00 p.m. (U.S. Eastern Time) on November 25, 2025, the voting record time for the Scheme Meeting and the EGM. The final results of voting on each of the proposals submitted are as follows.","length":639,"tagName":"p"},{"type":"text","content":"SCHEME MEETING","length":14...